Review



sars cov2 s1 b 1 351 beta  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Sino Biological sars cov2 s1 b 1 351 beta
    (A) Human IgG levels against SARS <t>CoV2</t> antigens, measured by GC-FP, for vaccinated individuals versus unvaccinated individuals. The Mann-Whitney test was used to determine statistical significance. (B) Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10 subjects, collected prevaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of vaccine. One-way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison testing was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).
    Sars Cov2 S1 B 1 351 Beta, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/codon+optimized+sars+cov2+spike/pmc08557906-8-0-8?v=Sino+Biological
    Average 90 stars, based on 1 article reviews
    sars cov2 s1 b 1 351 beta - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection"

    Article Title: Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

    Journal: Microbiology Spectrum

    doi: 10.1128/Spectrum.00890-21

    (A) Human IgG levels against SARS CoV2 antigens, measured by GC-FP, for vaccinated individuals versus unvaccinated individuals. The Mann-Whitney test was used to determine statistical significance. (B) Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10 subjects, collected prevaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of vaccine. One-way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison testing was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).
    Figure Legend Snippet: (A) Human IgG levels against SARS CoV2 antigens, measured by GC-FP, for vaccinated individuals versus unvaccinated individuals. The Mann-Whitney test was used to determine statistical significance. (B) Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10 subjects, collected prevaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of vaccine. One-way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison testing was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Techniques Used: MANN-WHITNEY, Sequencing

    IgG levels against SARS CoV2 antigens for uninfected, previously infected, and vaccinated individuals. Uninfected samples were collected prior to vaccination, from individuals who reported no prior COVID-19 symptoms, and tested negative via PCR and/or antibody testing ( n = 42). Other samples were from PCR-confirmed COVID-19-positive subjects who were hospitalized ( n = 3), PCR-confirmed COVID-19-positive subjects who were not hospitalized CoV2 ( n = 5), and previously COVID-19-positive subjects who received subsequent vaccination ( n = 9). Samples were also collected from subjects who were at least 2 weeks past full vaccination with Pfizer-BioNTech ( n = 17) or Moderna ( n = 8) or 2 weeks past receiving the Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).
    Figure Legend Snippet: IgG levels against SARS CoV2 antigens for uninfected, previously infected, and vaccinated individuals. Uninfected samples were collected prior to vaccination, from individuals who reported no prior COVID-19 symptoms, and tested negative via PCR and/or antibody testing ( n = 42). Other samples were from PCR-confirmed COVID-19-positive subjects who were hospitalized ( n = 3), PCR-confirmed COVID-19-positive subjects who were not hospitalized CoV2 ( n = 5), and previously COVID-19-positive subjects who received subsequent vaccination ( n = 9). Samples were also collected from subjects who were at least 2 weeks past full vaccination with Pfizer-BioNTech ( n = 17) or Moderna ( n = 8) or 2 weeks past receiving the Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Techniques Used: Infection

    Fold-difference in antibody levels against antigens from SARS CoV2 variant strains B.1.1.7 and B.1.351 versus antigens from the original 2019 SARS CoV2 strain. Samples included those from individuals who were hospitalized ( n = 3), nonhospitalized CoV2-positive ( n = 5), previously CoV2-positive with subsequent vaccination ( n = 9), and at least 2 weeks past vaccination with Pfizer-BioNTech ( n = 17), Moderna ( n = 8), or Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).
    Figure Legend Snippet: Fold-difference in antibody levels against antigens from SARS CoV2 variant strains B.1.1.7 and B.1.351 versus antigens from the original 2019 SARS CoV2 strain. Samples included those from individuals who were hospitalized ( n = 3), nonhospitalized CoV2-positive ( n = 5), previously CoV2-positive with subsequent vaccination ( n = 9), and at least 2 weeks past vaccination with Pfizer-BioNTech ( n = 17), Moderna ( n = 8), or Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Techniques Used: Variant Assay

    (A and B) IgG levels from dried blood spots measured by GC-FP diagnostic ratio compared to competitive ELISA by eluate from the same dried blood spot samples. Both GC-FP and ACE2 competitive binding were performed for RBD antigen from the original 2019 SARS CoV2 and the variant strains B.1.1.7 and B.1.351. Testing was performed with dried blood spots collected from vaccinated subjects (3 Pfizer-BioNTech, 3 Moderna, 2 Johnson & Johnson) and subjects who were both previously infected and then vaccinated with Pfizer-BioNTech or Moderna vaccines ( n = 3). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001). (C and D) The percentage of ACE2 binding inhibition from the competitive ELISA is shown for a dried blood spot sample (C) from a Pfizer-BioNTech-vaccinated subject and blood serum from a hospitalized, COVID-positive subject (D). Vertical dotted lines represent the dilution factor used in the corresponding GC-FP test for each sample. (E and F) The fold difference in binding inhibition and fold difference in GC-FP diagnostic ratio were plotted for variant antigens (RBD B.1.1.7 and RBD B.1.351) versus RBD 2019 CoV2.
    Figure Legend Snippet: (A and B) IgG levels from dried blood spots measured by GC-FP diagnostic ratio compared to competitive ELISA by eluate from the same dried blood spot samples. Both GC-FP and ACE2 competitive binding were performed for RBD antigen from the original 2019 SARS CoV2 and the variant strains B.1.1.7 and B.1.351. Testing was performed with dried blood spots collected from vaccinated subjects (3 Pfizer-BioNTech, 3 Moderna, 2 Johnson & Johnson) and subjects who were both previously infected and then vaccinated with Pfizer-BioNTech or Moderna vaccines ( n = 3). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001). (C and D) The percentage of ACE2 binding inhibition from the competitive ELISA is shown for a dried blood spot sample (C) from a Pfizer-BioNTech-vaccinated subject and blood serum from a hospitalized, COVID-positive subject (D). Vertical dotted lines represent the dilution factor used in the corresponding GC-FP test for each sample. (E and F) The fold difference in binding inhibition and fold difference in GC-FP diagnostic ratio were plotted for variant antigens (RBD B.1.1.7 and RBD B.1.351) versus RBD 2019 CoV2.

    Techniques Used: Diagnostic Assay, Competitive ELISA, Binding Assay, Variant Assay, Infection, Inhibition

    Proteins and peptides used for generating GC-FP detection microchips
    Figure Legend Snippet: Proteins and peptides used for generating GC-FP detection microchips

    Techniques Used: Positive Control, Negative Control



    Similar Products

    sars cov2 s1 b 1 351 beta  (Sino Biological)
    90
    Sino Biological sars cov2 s1 b 1 351 beta
    (A) Human IgG levels against SARS <t>CoV2</t> antigens, measured by GC-FP, for vaccinated individuals versus unvaccinated individuals. The Mann-Whitney test was used to determine statistical significance. (B) Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10 subjects, collected prevaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of vaccine. One-way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison testing was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).
    Sars Cov2 S1 B 1 351 Beta, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/codon+optimized+sars+cov2+spike/pmc08557906-8-0-8?v=Sino+Biological
    Average 90 stars, based on 1 article reviews
    sars cov2 s1 b 1 351 beta - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    codon optimized sars cov2 spike  (Sino Biological)
    90
    Sino Biological codon optimized sars cov2 spike
    (A) The functional domain of <t>SARS-CoV-2</t> spike protein. (B) Potential B cell antigen of RBD domain from <t>SARS-CoV2</t> is predicted by Discotope software based on their 3D structure. (C) Potential linear B cell epitopes of SARS-CoV-2 full S protein are analysed with the IEDB database. (D) The location of potential antigens in RBD domain (SARS-CoV-2:red, SARS-CoV: Purple) and interaction model between RBD and ACE2 receptor (interface is marked yellow) are marked with Discovery Studio. (E) The expression of Spike and nucleocapsid with wild-type sequence in 293T cells are detected by Western Blot assay. (F) The expression of Spike and its derivatives with codon optimization (opt).
    Codon Optimized Sars Cov2 Spike, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/codon+optimized+sars+cov2+spike/bio_rxiv__2020__08__19__258244-62-21-28?v=Sino+Biological
    Average 90 stars, based on 1 article reviews
    codon optimized sars cov2 spike - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Human IgG levels against SARS CoV2 antigens, measured by GC-FP, for vaccinated individuals versus unvaccinated individuals. The Mann-Whitney test was used to determine statistical significance. (B) Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10 subjects, collected prevaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of vaccine. One-way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison testing was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Journal: Microbiology Spectrum

    Article Title: Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

    doi: 10.1128/Spectrum.00890-21

    Figure Lengend Snippet: (A) Human IgG levels against SARS CoV2 antigens, measured by GC-FP, for vaccinated individuals versus unvaccinated individuals. The Mann-Whitney test was used to determine statistical significance. (B) Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10 subjects, collected prevaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of vaccine. One-way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison testing was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Article Snippet: SARS CoV2 S1—B.1.351/Beta (K417N, E484K, N501Y, D614G) , Sino Biological.

    Techniques: MANN-WHITNEY, Sequencing

    IgG levels against SARS CoV2 antigens for uninfected, previously infected, and vaccinated individuals. Uninfected samples were collected prior to vaccination, from individuals who reported no prior COVID-19 symptoms, and tested negative via PCR and/or antibody testing ( n = 42). Other samples were from PCR-confirmed COVID-19-positive subjects who were hospitalized ( n = 3), PCR-confirmed COVID-19-positive subjects who were not hospitalized CoV2 ( n = 5), and previously COVID-19-positive subjects who received subsequent vaccination ( n = 9). Samples were also collected from subjects who were at least 2 weeks past full vaccination with Pfizer-BioNTech ( n = 17) or Moderna ( n = 8) or 2 weeks past receiving the Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Journal: Microbiology Spectrum

    Article Title: Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

    doi: 10.1128/Spectrum.00890-21

    Figure Lengend Snippet: IgG levels against SARS CoV2 antigens for uninfected, previously infected, and vaccinated individuals. Uninfected samples were collected prior to vaccination, from individuals who reported no prior COVID-19 symptoms, and tested negative via PCR and/or antibody testing ( n = 42). Other samples were from PCR-confirmed COVID-19-positive subjects who were hospitalized ( n = 3), PCR-confirmed COVID-19-positive subjects who were not hospitalized CoV2 ( n = 5), and previously COVID-19-positive subjects who received subsequent vaccination ( n = 9). Samples were also collected from subjects who were at least 2 weeks past full vaccination with Pfizer-BioNTech ( n = 17) or Moderna ( n = 8) or 2 weeks past receiving the Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Article Snippet: SARS CoV2 S1—B.1.351/Beta (K417N, E484K, N501Y, D614G) , Sino Biological.

    Techniques: Infection

    Fold-difference in antibody levels against antigens from SARS CoV2 variant strains B.1.1.7 and B.1.351 versus antigens from the original 2019 SARS CoV2 strain. Samples included those from individuals who were hospitalized ( n = 3), nonhospitalized CoV2-positive ( n = 5), previously CoV2-positive with subsequent vaccination ( n = 9), and at least 2 weeks past vaccination with Pfizer-BioNTech ( n = 17), Moderna ( n = 8), or Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Journal: Microbiology Spectrum

    Article Title: Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

    doi: 10.1128/Spectrum.00890-21

    Figure Lengend Snippet: Fold-difference in antibody levels against antigens from SARS CoV2 variant strains B.1.1.7 and B.1.351 versus antigens from the original 2019 SARS CoV2 strain. Samples included those from individuals who were hospitalized ( n = 3), nonhospitalized CoV2-positive ( n = 5), previously CoV2-positive with subsequent vaccination ( n = 9), and at least 2 weeks past vaccination with Pfizer-BioNTech ( n = 17), Moderna ( n = 8), or Johnson & Johnson vaccine ( n = 9). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001).

    Article Snippet: SARS CoV2 S1—B.1.351/Beta (K417N, E484K, N501Y, D614G) , Sino Biological.

    Techniques: Variant Assay

    (A and B) IgG levels from dried blood spots measured by GC-FP diagnostic ratio compared to competitive ELISA by eluate from the same dried blood spot samples. Both GC-FP and ACE2 competitive binding were performed for RBD antigen from the original 2019 SARS CoV2 and the variant strains B.1.1.7 and B.1.351. Testing was performed with dried blood spots collected from vaccinated subjects (3 Pfizer-BioNTech, 3 Moderna, 2 Johnson & Johnson) and subjects who were both previously infected and then vaccinated with Pfizer-BioNTech or Moderna vaccines ( n = 3). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001). (C and D) The percentage of ACE2 binding inhibition from the competitive ELISA is shown for a dried blood spot sample (C) from a Pfizer-BioNTech-vaccinated subject and blood serum from a hospitalized, COVID-positive subject (D). Vertical dotted lines represent the dilution factor used in the corresponding GC-FP test for each sample. (E and F) The fold difference in binding inhibition and fold difference in GC-FP diagnostic ratio were plotted for variant antigens (RBD B.1.1.7 and RBD B.1.351) versus RBD 2019 CoV2.

    Journal: Microbiology Spectrum

    Article Title: Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

    doi: 10.1128/Spectrum.00890-21

    Figure Lengend Snippet: (A and B) IgG levels from dried blood spots measured by GC-FP diagnostic ratio compared to competitive ELISA by eluate from the same dried blood spot samples. Both GC-FP and ACE2 competitive binding were performed for RBD antigen from the original 2019 SARS CoV2 and the variant strains B.1.1.7 and B.1.351. Testing was performed with dried blood spots collected from vaccinated subjects (3 Pfizer-BioNTech, 3 Moderna, 2 Johnson & Johnson) and subjects who were both previously infected and then vaccinated with Pfizer-BioNTech or Moderna vaccines ( n = 3). One-way ANOVA followed by Dunnett’s multiple-comparison test was performed (*, P = 0.03; **, P = 0.002; ***, P = 0.0002; ****, P < 0.0001). (C and D) The percentage of ACE2 binding inhibition from the competitive ELISA is shown for a dried blood spot sample (C) from a Pfizer-BioNTech-vaccinated subject and blood serum from a hospitalized, COVID-positive subject (D). Vertical dotted lines represent the dilution factor used in the corresponding GC-FP test for each sample. (E and F) The fold difference in binding inhibition and fold difference in GC-FP diagnostic ratio were plotted for variant antigens (RBD B.1.1.7 and RBD B.1.351) versus RBD 2019 CoV2.

    Article Snippet: SARS CoV2 S1—B.1.351/Beta (K417N, E484K, N501Y, D614G) , Sino Biological.

    Techniques: Diagnostic Assay, Competitive ELISA, Binding Assay, Variant Assay, Infection, Inhibition

    Proteins and peptides used for generating GC-FP detection microchips

    Journal: Microbiology Spectrum

    Article Title: Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

    doi: 10.1128/Spectrum.00890-21

    Figure Lengend Snippet: Proteins and peptides used for generating GC-FP detection microchips

    Article Snippet: SARS CoV2 S1—B.1.351/Beta (K417N, E484K, N501Y, D614G) , Sino Biological.

    Techniques: Positive Control, Negative Control

    (A) The functional domain of SARS-CoV-2 spike protein. (B) Potential B cell antigen of RBD domain from SARS-CoV2 is predicted by Discotope software based on their 3D structure. (C) Potential linear B cell epitopes of SARS-CoV-2 full S protein are analysed with the IEDB database. (D) The location of potential antigens in RBD domain (SARS-CoV-2:red, SARS-CoV: Purple) and interaction model between RBD and ACE2 receptor (interface is marked yellow) are marked with Discovery Studio. (E) The expression of Spike and nucleocapsid with wild-type sequence in 293T cells are detected by Western Blot assay. (F) The expression of Spike and its derivatives with codon optimization (opt).

    Journal: bioRxiv

    Article Title: An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2

    doi: 10.1101/2020.08.19.258244

    Figure Lengend Snippet: (A) The functional domain of SARS-CoV-2 spike protein. (B) Potential B cell antigen of RBD domain from SARS-CoV2 is predicted by Discotope software based on their 3D structure. (C) Potential linear B cell epitopes of SARS-CoV-2 full S protein are analysed with the IEDB database. (D) The location of potential antigens in RBD domain (SARS-CoV-2:red, SARS-CoV: Purple) and interaction model between RBD and ACE2 receptor (interface is marked yellow) are marked with Discovery Studio. (E) The expression of Spike and nucleocapsid with wild-type sequence in 293T cells are detected by Western Blot assay. (F) The expression of Spike and its derivatives with codon optimization (opt).

    Article Snippet: The coding sequence of Spike, Nucleocapsid derived from SARS-COV2 (MN908947.3), and human IgG Fc fragment (BC065820.1) was synthesized by Sangon Biotech, codon optimized SARS-CoV2 spike was bought from Sino Biological.

    Techniques: Functional Assay, Software, Expressing, Sequencing, Western Blot

    (A) Potential B-cell epitopes of N protein is predicted by IEDB database. (B) Potential MHCI-binding peptides of N. (C) Functional domain of SARS-CoV N protein (Upper) and its antibody epitope map reported in previous study. (D) The skeleton of Chimeric Vaccine for SARS-CoV-2, RBD: spike RBD domain (306-541 aa), Ntap: T-cell-associated peptide of N (211-339 aa). (E) Characterization of SARS-CoV-2-derived protein and C-Vac antigen by SARS-CoV-2 antisera and commercial antibodies against SARS-CoV2 spike RBD or Nucleocapsid.

    Journal: bioRxiv

    Article Title: An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2

    doi: 10.1101/2020.08.19.258244

    Figure Lengend Snippet: (A) Potential B-cell epitopes of N protein is predicted by IEDB database. (B) Potential MHCI-binding peptides of N. (C) Functional domain of SARS-CoV N protein (Upper) and its antibody epitope map reported in previous study. (D) The skeleton of Chimeric Vaccine for SARS-CoV-2, RBD: spike RBD domain (306-541 aa), Ntap: T-cell-associated peptide of N (211-339 aa). (E) Characterization of SARS-CoV-2-derived protein and C-Vac antigen by SARS-CoV-2 antisera and commercial antibodies against SARS-CoV2 spike RBD or Nucleocapsid.

    Article Snippet: The coding sequence of Spike, Nucleocapsid derived from SARS-COV2 (MN908947.3), and human IgG Fc fragment (BC065820.1) was synthesized by Sangon Biotech, codon optimized SARS-CoV2 spike was bought from Sino Biological.

    Techniques: Binding Assay, Functional Assay, Derivative Assay